PRLD Prelude Therapeutics Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1678660 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY105.4%
TTM net income YoY52.3%
TTM EPS YoY59.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-283.9%
Net margin-247.1%
FCF margin-129.6%
EBITDA margin-277.0%
Returns
ROE-58.4%
ROA-39.5%
ROIC (approx.)-86.6%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets29.3%
Debt / equity0.00x
Current ratio4.20x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-18.8%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $12.14M | $7.00M |
| R&D expense | $94.30M | $118.00M |
| SG&A expense | $22.41M | $28.72M |
| Operating income | -$104.57M | -$139.71M |
| Pretax income | -$99.50M | -$127.20M |
| Income tax | $0 | $0 |
| Net income | -$99.50M | -$127.17M |
| EBITDA | -$102.86M | -$137.94M |
| EPS (basic) | -1.29 | -1.68 |
| EPS (diluted) | -1.29 | -1.68 |
| Weighted avg. shares (diluted) | 76.96M | 75.81M |
| Balance sheet | ||
| Cash & equivalents | $35.26M | $12.47M |
| Short-term investments | $67.96M | $121.14M |
| Current assets | $105.69M | $135.90M |
| PP&E, net | $5.11M | $6.77M |
| Total assets | $141.31M | $175.51M |
| Current liabilities | $52.99M | $25.64M |
| Total liabilities | $72.68M | $44.06M |
| Shareholders' equity | $68.64M | $131.46M |
| Cash flow statement | ||
| Operating cash flow | -$56.30M | -$102.89M |
| Capital expenditure | $67,000 | $764,000 |
| Free cash flow | -$56.37M | -$103.65M |
| Investing cash flow | $53.46M | $90.19M |
| Financing cash flow | $24.82M | -$120,000 |
| Depreciation & amortization | $1.71M | $1.77M |
| Stock-based compensation | $11.91M | $21.34M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.